PILA PHARMA
4.43
SEK
+0.45 %
PILA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+0.45%
-13.48%
-9.03%
+83.06%
+176.87%
+148.88%
-36.73%
-
-49.42%
pilapharma.com/investors
PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the painful rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.
Revenue
1.46M
EBIT %
-437.67 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
PILA
Daily low / high price
4.21 / 4.44
SEK
Market cap
120.17M SEK
Turnover
126.44K SEK
Volume
29K
Latest videos
Financial calendar
Annual report
2025-02-27
Interim report
2025-08-27
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Dorte X. Gram genom bolag | 19.2 % | 19.2 % |
| Vimpu Intressenter AB | 18.4 % | 18.4 % |
| Goldman Sachs & Co. | 3.3 % | 3.3 % |
| Peter Odsgaard | 2.0 % | 2.0 % |
| UBS Switzerland AG | 2.0 % | 2.0 % |
| JP Morgan Chase Bank NA | 1.7 % | 1.7 % |
| Saxo Bank A/S Client Assets | 1.7 % | 1.7 % |
| BNY Mellon Sa/Nv Frkn Jyske Bank | 1.6 % | 1.6 % |
| Nordnet Pensionsförsäkring | 1.3 % | 1.3 % |
| Aktieselskabet Arbejdernes Landsbank | 1.3 % | 1.3 % |
ShowingAll content types
PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS
PILA PHARMA AB Chairman & CEO increase their holdings
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools